Zolpidem has been observed to transiently treat a large variety of neurologic disorders, most often related to movement disorders and disorders of consciousness.
A systematic review was conducted of 67 studies with a total of 557 patients: it included 31 studies that treated movement disorders, 22 studies that treated disorders of consciousness, and 14 studies that treated other neurologic conditions, including stroke, traumatic brain injury, encephalopathy, and dementia.
Many studies were case reports and small interventional trials. The most common dose was 10 mg zolpidem across all the disorders of consciousness studies.
Zolpidem effects were wide ranging. They included improvement on the JFK Coma Recovery Scale–Revised, the Unified Parkinson Disease Rating Scale, and the Burke-Fahn-Marsden Dystonia Rating Scale, and generally lasted 1 to 4 hours. The drug response rate was 18% or higher for the patients with movement disorders, such as Parkinson's disease or dystonia, and was 5%-7% in those with disorders of consciousness.